Chemotherapy is the primary treatment for non-Hodgkin lymphoma, though people may also receive it with immunotherapy. Chemotherapy remains the first-line treatment for non-Hodgkin lymphoma (NHL), a ...

Cardiovascular and hematologic complications of Hodgkin vs non-Hodgkin lymphoma and readmission trends: A National Readmission Database analysis from years 2016-2020. Real-world cost of disease ...

Epcoritamab addition to R2 significantly improves progression-free survival and overall response rates in relapsed follicular ...

Roche (ROG: SIX) has unveiled a fresh wave of data for Lunsumio (mosunetuzumab), underscoring the Swiss pharma major’s ...

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data highlighting the potential of ...

R 2 is the only second-line alternative to chemoimmunotherapy-based treatment for patients with relapsed/refractory ...

Leveraging Implementation Science to Optimize Strategies for Cancer Control in Mexico and Latin America We enrolled 55 patients with low grade lymphoma. Median age was 58 (range 28-82), 35 (64%) were ...

Roche (RHHBY) announced new data highlighting the potential of Lunsumio, mosunetuzumab, in earlier treatment lines for people ...

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction ...

In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.

“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...